nodes	percent_of_prediction	percent_of_DWPC	metapath
Nicotine—CYP2A13—Methoxsalen—psoriasis	0.352	0.476	CbGbCtD
Nicotine—CYP1A1—Clobetasol propionate—psoriasis	0.0466	0.063	CbGbCtD
Nicotine—CYP2A6—Methoxsalen—psoriasis	0.0286	0.0387	CbGbCtD
Nicotine—CYP1A1—Methoxsalen—psoriasis	0.0245	0.0331	CbGbCtD
Nicotine—CYP19A1—Betamethasone—psoriasis	0.0223	0.0301	CbGbCtD
Nicotine—CYP2C8—Tazarotene—psoriasis	0.0219	0.0296	CbGbCtD
Nicotine—CYP1A2—Clobetasol propionate—psoriasis	0.0208	0.0281	CbGbCtD
Nicotine—CYP1A1—Cholecalciferol—psoriasis	0.0162	0.0219	CbGbCtD
Nicotine—CYP2A6—Prednisolone—psoriasis	0.0139	0.0188	CbGbCtD
Nicotine—CYP19A1—Dexamethasone—psoriasis	0.013	0.0175	CbGbCtD
Nicotine—CYP2B6—Cholecalciferol—psoriasis	0.0123	0.0167	CbGbCtD
Nicotine—CYP1A2—Methoxsalen—psoriasis	0.0109	0.0148	CbGbCtD
Nicotine—CYP2D6—Hydroxyurea—psoriasis	0.00984	0.0133	CbGbCtD
Nicotine—CYP2C8—Cholecalciferol—psoriasis	0.00935	0.0127	CbGbCtD
Nicotine—CYP2A6—Dexamethasone—psoriasis	0.0082	0.0111	CbGbCtD
Nicotine—CYP2C8—Mycophenolate mofetil—psoriasis	0.00811	0.011	CbGbCtD
Nicotine—CYP2C19—Cholecalciferol—psoriasis	0.00784	0.0106	CbGbCtD
Nicotine—CYP3A4—Calcitriol—psoriasis	0.00736	0.00996	CbGbCtD
Nicotine—CYP1A1—Dexamethasone—psoriasis	0.00701	0.00949	CbGbCtD
Nicotine—CYP2C9—Cholecalciferol—psoriasis	0.00652	0.00882	CbGbCtD
Nicotine—CYP2C8—Hydrocortisone—psoriasis	0.00651	0.0088	CbGbCtD
Nicotine—CYP2C8—Cyclosporine—psoriasis	0.00614	0.00831	CbGbCtD
Nicotine—CYP2D6—Cholecalciferol—psoriasis	0.00596	0.00807	CbGbCtD
Nicotine—CYP3A4—Methoxsalen—psoriasis	0.00572	0.00775	CbGbCtD
Nicotine—CYP2C19—Prednisone—psoriasis	0.00544	0.00736	CbGbCtD
Nicotine—CYP2E1—Dexamethasone—psoriasis	0.00541	0.00733	CbGbCtD
Nicotine—CYP2B6—Dexamethasone—psoriasis	0.00534	0.00723	CbGbCtD
Nicotine—CYP2C19—Cyclosporine—psoriasis	0.00515	0.00697	CbGbCtD
Nicotine—CYP2C9—Cyclosporine—psoriasis	0.00428	0.0058	CbGbCtD
Nicotine—CYP2C8—Dexamethasone—psoriasis	0.00405	0.00547	CbGbCtD
Nicotine—CYP2D6—Cyclosporine—psoriasis	0.00392	0.0053	CbGbCtD
Nicotine—CYP3A4—Cholecalciferol—psoriasis	0.00379	0.00513	CbGbCtD
Nicotine—CYP2C19—Dexamethasone—psoriasis	0.00339	0.00459	CbGbCtD
Nicotine—CYP3A4—Triamcinolone—psoriasis	0.00329	0.00445	CbGbCtD
Nicotine—CYP3A4—Mycophenolate mofetil—psoriasis	0.00329	0.00445	CbGbCtD
Nicotine—CYP2C9—Dexamethasone—psoriasis	0.00282	0.00382	CbGbCtD
Nicotine—CYP3A4—Betamethasone—psoriasis	0.00282	0.00382	CbGbCtD
Nicotine—CYP3A4—Prednisolone—psoriasis	0.00278	0.00377	CbGbCtD
Nicotine—CYP3A4—Hydrocortisone—psoriasis	0.00264	0.00357	CbGbCtD
Nicotine—CYP3A4—Prednisone—psoriasis	0.00263	0.00356	CbGbCtD
Nicotine—CYP2D6—Dexamethasone—psoriasis	0.00258	0.00349	CbGbCtD
Nicotine—CYP3A4—Cyclosporine—psoriasis	0.00249	0.00337	CbGbCtD
Nicotine—CYP3A4—Dexamethasone—psoriasis	0.00164	0.00222	CbGbCtD
Nicotine—CHRNA3—skin epidermis—psoriasis	0.000562	0.206	CbGeAlD
Nicotine—CHRNA7—skin epidermis—psoriasis	0.000367	0.135	CbGeAlD
Nicotine—CHRNA6—skin of body—psoriasis	0.000313	0.115	CbGeAlD
Nicotine—CHRNB4—tendon—psoriasis	0.000216	0.0792	CbGeAlD
Nicotine—CHRNA10—tendon—psoriasis	0.00019	0.0697	CbGeAlD
Nicotine—CYP1A1—skin epidermis—psoriasis	0.00019	0.0697	CbGeAlD
Nicotine—CHRNA3—skin of body—psoriasis	0.000174	0.0638	CbGeAlD
Nicotine—CHRNB2—tendon—psoriasis	0.000137	0.0501	CbGeAlD
Nicotine—CHAT—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000132	0.00206	CbGpPWpGaD
Nicotine—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000132	0.00206	CbGpPWpGaD
Nicotine—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000132	0.00206	CbGpPWpGaD
Nicotine—MAOA—Oxidative Stress—NFKB1—psoriasis	0.00013	0.00203	CbGpPWpGaD
Nicotine—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.00013	0.00203	CbGpPWpGaD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—IL10—psoriasis	0.000129	0.00202	CbGpPWpGaD
Nicotine—CHRNB2—Circadian rythm related genes—LEP—psoriasis	0.000127	0.00199	CbGpPWpGaD
Nicotine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000124	0.00194	CbGpPWpGaD
Nicotine—CHAT—SIDS Susceptibility Pathways—JUN—psoriasis	0.000123	0.00192	CbGpPWpGaD
Nicotine—CYP2C8—Biological oxidations—CYP2S1—psoriasis	0.000123	0.00192	CbGpPWpGaD
Nicotine—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000122	0.00191	CbGpPWpGaD
Nicotine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000122	0.00191	CbGpPWpGaD
Nicotine—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	0.000121	0.00189	CbGpPWpGaD
Nicotine—CHRNB2—Circadian rythm related genes—NOS2—psoriasis	0.000119	0.00185	CbGpPWpGaD
Nicotine—CHAT—SIDS Susceptibility Pathways—NFKB1—psoriasis	0.000118	0.00185	CbGpPWpGaD
Nicotine—CYP1A1—Tryptophan metabolism—CAT—psoriasis	0.000115	0.0018	CbGpPWpGaD
Nicotine—SLC22A3—SLC-mediated transmembrane transport—CP—psoriasis	0.000115	0.00179	CbGpPWpGaD
Nicotine—CYP2A13—Metabolism—CYP2S1—psoriasis	0.000114	0.00179	CbGpPWpGaD
Nicotine—SLC22A5—SLC-mediated transmembrane transport—CP—psoriasis	0.000114	0.00179	CbGpPWpGaD
Nicotine—CHRNA7—skin of body—psoriasis	0.000114	0.0417	CbGeAlD
Nicotine—MAOA—SIDS Susceptibility Pathways—IL13—psoriasis	0.000113	0.00177	CbGpPWpGaD
Nicotine—CHRNB2—Circadian rythm related genes—PPARG—psoriasis	0.000111	0.00173	CbGpPWpGaD
Nicotine—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000109	0.00171	CbGpPWpGaD
Nicotine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000108	0.00169	CbGpPWpGaD
Nicotine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000108	0.00168	CbGpPWpGaD
Nicotine—CHAT—SIDS Susceptibility Pathways—VEGFA—psoriasis	0.000107	0.00168	CbGpPWpGaD
Nicotine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000106	0.00166	CbGpPWpGaD
Nicotine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000106	0.00166	CbGpPWpGaD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—IL10—psoriasis	0.000106	0.00165	CbGpPWpGaD
Nicotine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000106	0.00165	CbGpPWpGaD
Nicotine—CHRNB2—SIDS Susceptibility Pathways—CXCL8—psoriasis	0.000104	0.00162	CbGpPWpGaD
Nicotine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000101	0.00157	CbGpPWpGaD
Nicotine—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.0001	0.00156	CbGpPWpGaD
Nicotine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	9.98e-05	0.00156	CbGpPWpGaD
Nicotine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	9.93e-05	0.00155	CbGpPWpGaD
Nicotine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	9.84e-05	0.00154	CbGpPWpGaD
Nicotine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	9.76e-05	0.00153	CbGpPWpGaD
Nicotine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	9.71e-05	0.00152	CbGpPWpGaD
Nicotine—CHRNB2—SIDS Susceptibility Pathways—JUN—psoriasis	9.63e-05	0.00151	CbGpPWpGaD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	9.5e-05	0.00149	CbGpPWpGaD
Nicotine—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	9.34e-05	0.00146	CbGpPWpGaD
Nicotine—CHRNB2—SIDS Susceptibility Pathways—NFKB1—psoriasis	9.27e-05	0.00145	CbGpPWpGaD
Nicotine—CHAT—SIDS Susceptibility Pathways—TNF—psoriasis	9.19e-05	0.00144	CbGpPWpGaD
Nicotine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	9.14e-05	0.00143	CbGpPWpGaD
Nicotine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.1e-05	0.00142	CbGpPWpGaD
Nicotine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	8.53e-05	0.00133	CbGpPWpGaD
Nicotine—CHRNB2—SIDS Susceptibility Pathways—VEGFA—psoriasis	8.41e-05	0.00132	CbGpPWpGaD
Nicotine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	8.41e-05	0.00132	CbGpPWpGaD
Nicotine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	8.4e-05	0.00131	CbGpPWpGaD
Nicotine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	8.27e-05	0.00129	CbGpPWpGaD
Nicotine—CHRNB4—SIDS Susceptibility Pathways—CXCL8—psoriasis	8.15e-05	0.00127	CbGpPWpGaD
Nicotine—Hypotension—Hydrocortisone—psoriasis	8.01e-05	0.000412	CcSEcCtD
Nicotine—Feeling abnormal—Cyclosporine—psoriasis	7.95e-05	0.000409	CcSEcCtD
Nicotine—Shock—Triamcinolone—psoriasis	7.94e-05	0.000409	CcSEcCtD
Nicotine—Insomnia—Prednisolone—psoriasis	7.94e-05	0.000408	CcSEcCtD
Nicotine—Gastrointestinal pain—Cyclosporine—psoriasis	7.89e-05	0.000406	CcSEcCtD
Nicotine—Loss of consciousness—Betamethasone—psoriasis	7.89e-05	0.000406	CcSEcCtD
Nicotine—Loss of consciousness—Dexamethasone—psoriasis	7.89e-05	0.000406	CcSEcCtD
Nicotine—Dizziness—Mycophenolic acid—psoriasis	7.88e-05	0.000406	CcSEcCtD
Nicotine—Epistaxis—Methotrexate—psoriasis	7.88e-05	0.000406	CcSEcCtD
Nicotine—Paraesthesia—Prednisolone—psoriasis	7.88e-05	0.000406	CcSEcCtD
Nicotine—Tachycardia—Triamcinolone—psoriasis	7.88e-05	0.000405	CcSEcCtD
Nicotine—Mental disorder—Prednisone—psoriasis	7.86e-05	0.000405	CcSEcCtD
Nicotine—CHRNB2—Circadian rythm related genes—JUN—psoriasis	7.86e-05	0.00123	CbGpPWpGaD
Nicotine—Erythema—Prednisone—psoriasis	7.81e-05	0.000402	CcSEcCtD
Nicotine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.81e-05	0.000402	CcSEcCtD
Nicotine—Hyperhidrosis—Triamcinolone—psoriasis	7.8e-05	0.000401	CcSEcCtD
Nicotine—Convulsion—Betamethasone—psoriasis	7.77e-05	0.0004	CcSEcCtD
Nicotine—Convulsion—Dexamethasone—psoriasis	7.77e-05	0.0004	CcSEcCtD
Nicotine—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.75e-05	0.000399	CcSEcCtD
Nicotine—Insomnia—Hydrocortisone—psoriasis	7.75e-05	0.000399	CcSEcCtD
Nicotine—Hypertension—Dexamethasone—psoriasis	7.75e-05	0.000399	CcSEcCtD
Nicotine—Hypertension—Betamethasone—psoriasis	7.75e-05	0.000399	CcSEcCtD
Nicotine—SLC22A4—Transmembrane transport of small molecules—CP—psoriasis	7.73e-05	0.00121	CbGpPWpGaD
Nicotine—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	7.71e-05	0.00121	CbGpPWpGaD
Nicotine—Paraesthesia—Hydrocortisone—psoriasis	7.7e-05	0.000396	CcSEcCtD
Nicotine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.69e-05	0.000396	CcSEcCtD
Nicotine—Urticaria—Cyclosporine—psoriasis	7.66e-05	0.000394	CcSEcCtD
Nicotine—Myalgia—Betamethasone—psoriasis	7.64e-05	0.000393	CcSEcCtD
Nicotine—Myalgia—Dexamethasone—psoriasis	7.64e-05	0.000393	CcSEcCtD
Nicotine—Abdominal pain—Cyclosporine—psoriasis	7.62e-05	0.000392	CcSEcCtD
Nicotine—Body temperature increased—Cyclosporine—psoriasis	7.62e-05	0.000392	CcSEcCtD
Nicotine—Anxiety—Dexamethasone—psoriasis	7.61e-05	0.000392	CcSEcCtD
Nicotine—Anxiety—Betamethasone—psoriasis	7.61e-05	0.000392	CcSEcCtD
Nicotine—SLC22A4—tendon—psoriasis	7.59e-05	0.0278	CbGeAlD
Nicotine—CHRNB4—SIDS Susceptibility Pathways—JUN—psoriasis	7.58e-05	0.00119	CbGpPWpGaD
Nicotine—Vomiting—Mycophenolic acid—psoriasis	7.58e-05	0.00039	CcSEcCtD
Nicotine—Discomfort—Dexamethasone—psoriasis	7.55e-05	0.000388	CcSEcCtD
Nicotine—Discomfort—Betamethasone—psoriasis	7.55e-05	0.000388	CcSEcCtD
Nicotine—Dyspepsia—Hydrocortisone—psoriasis	7.54e-05	0.000388	CcSEcCtD
Nicotine—Rash—Mycophenolic acid—psoriasis	7.52e-05	0.000387	CcSEcCtD
Nicotine—Dermatitis—Mycophenolic acid—psoriasis	7.51e-05	0.000386	CcSEcCtD
Nicotine—CYP1A1—Oxidative Stress—NFKB1—psoriasis	7.51e-05	0.00117	CbGpPWpGaD
Nicotine—Pain—Prednisolone—psoriasis	7.5e-05	0.000386	CcSEcCtD
Nicotine—Urticaria—Mycophenolate mofetil—psoriasis	7.47e-05	0.000385	CcSEcCtD
Nicotine—Headache—Mycophenolic acid—psoriasis	7.47e-05	0.000384	CcSEcCtD
Nicotine—Pharyngitis—Methotrexate—psoriasis	7.44e-05	0.000383	CcSEcCtD
Nicotine—Abdominal pain—Mycophenolate mofetil—psoriasis	7.44e-05	0.000383	CcSEcCtD
Nicotine—Body temperature increased—Mycophenolate mofetil—psoriasis	7.44e-05	0.000383	CcSEcCtD
Nicotine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	7.42e-05	0.00116	CbGpPWpGaD
Nicotine—CHAT—SIDS Susceptibility Pathways—IL6—psoriasis	7.41e-05	0.00116	CbGpPWpGaD
Nicotine—MAOB—Metabolism—NDUFA5—psoriasis	7.41e-05	0.00116	CbGpPWpGaD
Nicotine—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.4e-05	0.000381	CcSEcCtD
Nicotine—Fatigue—Hydrocortisone—psoriasis	7.39e-05	0.00038	CcSEcCtD
Nicotine—SLC22A4—Transmembrane transport of small molecules—CARM1—psoriasis	7.37e-05	0.00115	CbGpPWpGaD
Nicotine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	7.36e-05	0.00115	CbGpPWpGaD
Nicotine—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.35e-05	0.000378	CcSEcCtD
Nicotine—Pain—Hydrocortisone—psoriasis	7.33e-05	0.000377	CcSEcCtD
Nicotine—Oedema—Dexamethasone—psoriasis	7.32e-05	0.000377	CcSEcCtD
Nicotine—Anaphylactic shock—Betamethasone—psoriasis	7.32e-05	0.000377	CcSEcCtD
Nicotine—Anaphylactic shock—Dexamethasone—psoriasis	7.32e-05	0.000377	CcSEcCtD
Nicotine—Oedema—Betamethasone—psoriasis	7.32e-05	0.000377	CcSEcCtD
Nicotine—Insomnia—Triamcinolone—psoriasis	7.3e-05	0.000376	CcSEcCtD
Nicotine—CHRNB4—SIDS Susceptibility Pathways—NFKB1—psoriasis	7.3e-05	0.00114	CbGpPWpGaD
Nicotine—Ill-defined disorder—Prednisone—psoriasis	7.25e-05	0.000373	CcSEcCtD
Nicotine—Paraesthesia—Triamcinolone—psoriasis	7.25e-05	0.000373	CcSEcCtD
Nicotine—Feeling abnormal—Prednisolone—psoriasis	7.23e-05	0.000372	CcSEcCtD
Nicotine—Visual impairment—Methotrexate—psoriasis	7.23e-05	0.000372	CcSEcCtD
Nicotine—CHRNB2—SIDS Susceptibility Pathways—TNF—psoriasis	7.21e-05	0.00113	CbGpPWpGaD
Nicotine—Shock—Dexamethasone—psoriasis	7.2e-05	0.000371	CcSEcCtD
Nicotine—Shock—Betamethasone—psoriasis	7.2e-05	0.000371	CcSEcCtD
Nicotine—Dyspnoea—Triamcinolone—psoriasis	7.19e-05	0.00037	CcSEcCtD
Nicotine—SLC22A2—SLC-mediated transmembrane transport—CP—psoriasis	7.19e-05	0.00112	CbGpPWpGaD
Nicotine—Nervous system disorder—Betamethasone—psoriasis	7.18e-05	0.00037	CcSEcCtD
Nicotine—Nervous system disorder—Dexamethasone—psoriasis	7.18e-05	0.00037	CcSEcCtD
Nicotine—Agitation—Prednisone—psoriasis	7.18e-05	0.00037	CcSEcCtD
Nicotine—Tachycardia—Betamethasone—psoriasis	7.15e-05	0.000368	CcSEcCtD
Nicotine—Tachycardia—Dexamethasone—psoriasis	7.15e-05	0.000368	CcSEcCtD
Nicotine—Angioedema—Prednisone—psoriasis	7.14e-05	0.000367	CcSEcCtD
Nicotine—Hypersensitivity—Cyclosporine—psoriasis	7.1e-05	0.000366	CcSEcCtD
Nicotine—Dyspepsia—Triamcinolone—psoriasis	7.1e-05	0.000366	CcSEcCtD
Nicotine—MAOA—SIDS Susceptibility Pathways—IL10—psoriasis	7.09e-05	0.00111	CbGpPWpGaD
Nicotine—Nausea—Mycophenolic acid—psoriasis	7.08e-05	0.000364	CcSEcCtD
Nicotine—Hyperhidrosis—Dexamethasone—psoriasis	7.08e-05	0.000364	CcSEcCtD
Nicotine—Hyperhidrosis—Betamethasone—psoriasis	7.08e-05	0.000364	CcSEcCtD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.08e-05	0.00111	CbGpPWpGaD
Nicotine—Feeling abnormal—Hydrocortisone—psoriasis	7.06e-05	0.000363	CcSEcCtD
Nicotine—CHAT—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.05e-05	0.0011	CbGpPWpGaD
Nicotine—Malaise—Prednisone—psoriasis	7.05e-05	0.000363	CcSEcCtD
Nicotine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.02e-05	0.0011	CbGpPWpGaD
Nicotine—Vertigo—Prednisone—psoriasis	7.02e-05	0.000361	CcSEcCtD
Nicotine—Gastrointestinal pain—Hydrocortisone—psoriasis	7.01e-05	0.000361	CcSEcCtD
Nicotine—Syncope—Prednisone—psoriasis	7.01e-05	0.000361	CcSEcCtD
Nicotine—Urticaria—Prednisolone—psoriasis	6.97e-05	0.000359	CcSEcCtD
Nicotine—Cardiac disorder—Methotrexate—psoriasis	6.96e-05	0.000358	CcSEcCtD
Nicotine—Fatigue—Triamcinolone—psoriasis	6.96e-05	0.000358	CcSEcCtD
Nicotine—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.93e-05	0.000357	CcSEcCtD
Nicotine—Asthenia—Cyclosporine—psoriasis	6.92e-05	0.000356	CcSEcCtD
Nicotine—Pain—Triamcinolone—psoriasis	6.9e-05	0.000355	CcSEcCtD
Nicotine—Loss of consciousness—Prednisone—psoriasis	6.87e-05	0.000353	CcSEcCtD
Nicotine—Hypotension—Betamethasone—psoriasis	6.84e-05	0.000352	CcSEcCtD
Nicotine—Hypotension—Dexamethasone—psoriasis	6.84e-05	0.000352	CcSEcCtD
Nicotine—Pruritus—Cyclosporine—psoriasis	6.82e-05	0.000351	CcSEcCtD
Nicotine—Urticaria—Hydrocortisone—psoriasis	6.81e-05	0.00035	CcSEcCtD
Nicotine—Immune system disorder—Methotrexate—psoriasis	6.77e-05	0.000349	CcSEcCtD
Nicotine—Abdominal pain—Hydrocortisone—psoriasis	6.77e-05	0.000349	CcSEcCtD
Nicotine—Body temperature increased—Hydrocortisone—psoriasis	6.77e-05	0.000349	CcSEcCtD
Nicotine—Convulsion—Prednisone—psoriasis	6.77e-05	0.000348	CcSEcCtD
Nicotine—Mediastinal disorder—Methotrexate—psoriasis	6.76e-05	0.000348	CcSEcCtD
Nicotine—Asthenia—Mycophenolate mofetil—psoriasis	6.75e-05	0.000347	CcSEcCtD
Nicotine—Hypertension—Prednisone—psoriasis	6.75e-05	0.000347	CcSEcCtD
Nicotine—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	6.7e-05	0.00105	CbGpPWpGaD
Nicotine—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.67e-05	0.000343	CcSEcCtD
Nicotine—Musculoskeletal discomfort—Betamethasone—psoriasis	6.67e-05	0.000343	CcSEcCtD
Nicotine—Pruritus—Mycophenolate mofetil—psoriasis	6.66e-05	0.000343	CcSEcCtD
Nicotine—Arthralgia—Prednisone—psoriasis	6.65e-05	0.000342	CcSEcCtD
Nicotine—Myalgia—Prednisone—psoriasis	6.65e-05	0.000342	CcSEcCtD
Nicotine—Feeling abnormal—Triamcinolone—psoriasis	6.65e-05	0.000342	CcSEcCtD
Nicotine—Anxiety—Prednisone—psoriasis	6.63e-05	0.000341	CcSEcCtD
Nicotine—CHRNB4—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.62e-05	0.00104	CbGpPWpGaD
Nicotine—Insomnia—Betamethasone—psoriasis	6.62e-05	0.000341	CcSEcCtD
Nicotine—Insomnia—Dexamethasone—psoriasis	6.62e-05	0.000341	CcSEcCtD
Nicotine—Diarrhoea—Cyclosporine—psoriasis	6.6e-05	0.00034	CcSEcCtD
Nicotine—SLC22A5—skin of body—psoriasis	6.6e-05	0.0241	CbGeAlD
Nicotine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	6.58e-05	0.00103	CbGpPWpGaD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—JUN—psoriasis	6.58e-05	0.00103	CbGpPWpGaD
Nicotine—Paraesthesia—Dexamethasone—psoriasis	6.57e-05	0.000338	CcSEcCtD
Nicotine—Paraesthesia—Betamethasone—psoriasis	6.57e-05	0.000338	CcSEcCtD
Nicotine—CHAT—Metabolism—CARM1—psoriasis	6.57e-05	0.00103	CbGpPWpGaD
Nicotine—Discomfort—Prednisone—psoriasis	6.57e-05	0.000338	CcSEcCtD
Nicotine—Mental disorder—Methotrexate—psoriasis	6.57e-05	0.000338	CcSEcCtD
Nicotine—Erythema—Methotrexate—psoriasis	6.53e-05	0.000336	CcSEcCtD
Nicotine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	6.49e-05	0.00101	CbGpPWpGaD
Nicotine—Hypersensitivity—Prednisolone—psoriasis	6.46e-05	0.000333	CcSEcCtD
Nicotine—Dyspepsia—Dexamethasone—psoriasis	6.45e-05	0.000332	CcSEcCtD
Nicotine—Dyspepsia—Betamethasone—psoriasis	6.45e-05	0.000332	CcSEcCtD
Nicotine—Diarrhoea—Mycophenolate mofetil—psoriasis	6.44e-05	0.000331	CcSEcCtD
Nicotine—Urticaria—Triamcinolone—psoriasis	6.41e-05	0.00033	CcSEcCtD
Nicotine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	6.41e-05	0.001	CbGpPWpGaD
Nicotine—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	6.4e-05	0.001	CbGpPWpGaD
Nicotine—Dysgeusia—Methotrexate—psoriasis	6.39e-05	0.000329	CcSEcCtD
Nicotine—MAOB—tendon—psoriasis	6.39e-05	0.0234	CbGeAlD
Nicotine—Body temperature increased—Triamcinolone—psoriasis	6.38e-05	0.000328	CcSEcCtD
Nicotine—Dizziness—Cyclosporine—psoriasis	6.38e-05	0.000328	CcSEcCtD
Nicotine—Anaphylactic shock—Prednisone—psoriasis	6.38e-05	0.000328	CcSEcCtD
Nicotine—Oedema—Prednisone—psoriasis	6.38e-05	0.000328	CcSEcCtD
Nicotine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.34e-05	0.000992	CbGpPWpGaD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.33e-05	0.00099	CbGpPWpGaD
Nicotine—Gastrointestinal disorder—Dexamethasone—psoriasis	6.32e-05	0.000325	CcSEcCtD
Nicotine—Gastrointestinal disorder—Betamethasone—psoriasis	6.32e-05	0.000325	CcSEcCtD
Nicotine—Back pain—Methotrexate—psoriasis	6.32e-05	0.000325	CcSEcCtD
Nicotine—Hypersensitivity—Hydrocortisone—psoriasis	6.31e-05	0.000325	CcSEcCtD
Nicotine—Fatigue—Betamethasone—psoriasis	6.31e-05	0.000325	CcSEcCtD
Nicotine—Fatigue—Dexamethasone—psoriasis	6.31e-05	0.000325	CcSEcCtD
Nicotine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.31e-05	0.000987	CbGpPWpGaD
Nicotine—MAOB—Metabolism—CYP2S1—psoriasis	6.3e-05	0.000985	CbGpPWpGaD
Nicotine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	6.3e-05	0.000985	CbGpPWpGaD
Nicotine—Shock—Prednisone—psoriasis	6.27e-05	0.000323	CcSEcCtD
Nicotine—SLC22A3—Metabolism—NDUFA5—psoriasis	6.27e-05	0.00098	CbGpPWpGaD
Nicotine—Pain—Dexamethasone—psoriasis	6.26e-05	0.000322	CcSEcCtD
Nicotine—Pain—Betamethasone—psoriasis	6.26e-05	0.000322	CcSEcCtD
Nicotine—Nervous system disorder—Prednisone—psoriasis	6.25e-05	0.000322	CcSEcCtD
Nicotine—Tachycardia—Prednisone—psoriasis	6.22e-05	0.00032	CcSEcCtD
Nicotine—Dizziness—Mycophenolate mofetil—psoriasis	6.22e-05	0.00032	CcSEcCtD
Nicotine—Hyperhidrosis—Prednisone—psoriasis	6.16e-05	0.000317	CcSEcCtD
Nicotine—Asthenia—Hydrocortisone—psoriasis	6.15e-05	0.000316	CcSEcCtD
Nicotine—CHAT—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.14e-05	0.000961	CbGpPWpGaD
Nicotine—Vomiting—Cyclosporine—psoriasis	6.13e-05	0.000316	CcSEcCtD
Nicotine—Rash—Cyclosporine—psoriasis	6.08e-05	0.000313	CcSEcCtD
Nicotine—Dermatitis—Cyclosporine—psoriasis	6.07e-05	0.000313	CcSEcCtD
Nicotine—Pruritus—Hydrocortisone—psoriasis	6.06e-05	0.000312	CcSEcCtD
Nicotine—Ill-defined disorder—Methotrexate—psoriasis	6.06e-05	0.000312	CcSEcCtD
Nicotine—Headache—Cyclosporine—psoriasis	6.04e-05	0.000311	CcSEcCtD
Nicotine—Feeling abnormal—Betamethasone—psoriasis	6.03e-05	0.000311	CcSEcCtD
Nicotine—Feeling abnormal—Dexamethasone—psoriasis	6.03e-05	0.000311	CcSEcCtD
Nicotine—Gastrointestinal pain—Betamethasone—psoriasis	5.99e-05	0.000308	CcSEcCtD
Nicotine—Gastrointestinal pain—Dexamethasone—psoriasis	5.99e-05	0.000308	CcSEcCtD
Nicotine—Vomiting—Mycophenolate mofetil—psoriasis	5.98e-05	0.000308	CcSEcCtD
Nicotine—Hypersensitivity—Triamcinolone—psoriasis	5.95e-05	0.000306	CcSEcCtD
Nicotine—Rash—Mycophenolate mofetil—psoriasis	5.93e-05	0.000305	CcSEcCtD
Nicotine—Dermatitis—Mycophenolate mofetil—psoriasis	5.93e-05	0.000305	CcSEcCtD
Nicotine—CYP1A1—skin of body—psoriasis	5.89e-05	0.0216	CbGeAlD
Nicotine—Headache—Mycophenolate mofetil—psoriasis	5.89e-05	0.000303	CcSEcCtD
Nicotine—Malaise—Methotrexate—psoriasis	5.89e-05	0.000303	CcSEcCtD
Nicotine—Vertigo—Methotrexate—psoriasis	5.87e-05	0.000302	CcSEcCtD
Nicotine—Diarrhoea—Hydrocortisone—psoriasis	5.86e-05	0.000302	CcSEcCtD
Nicotine—SLC22A3—Transmembrane transport of small molecules—CP—psoriasis	5.83e-05	0.000911	CbGpPWpGaD
Nicotine—CHRNB2—SIDS Susceptibility Pathways—IL6—psoriasis	5.82e-05	0.00091	CbGpPWpGaD
Nicotine—Urticaria—Dexamethasone—psoriasis	5.82e-05	0.000299	CcSEcCtD
Nicotine—Urticaria—Betamethasone—psoriasis	5.82e-05	0.000299	CcSEcCtD
Nicotine—Musculoskeletal discomfort—Prednisone—psoriasis	5.81e-05	0.000299	CcSEcCtD
Nicotine—SLC22A5—Transmembrane transport of small molecules—CP—psoriasis	5.81e-05	0.000908	CbGpPWpGaD
Nicotine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.81e-05	0.000908	CbGpPWpGaD
Nicotine—Dizziness—Prednisolone—psoriasis	5.8e-05	0.000299	CcSEcCtD
Nicotine—Asthenia—Triamcinolone—psoriasis	5.79e-05	0.000298	CcSEcCtD
Nicotine—Body temperature increased—Betamethasone—psoriasis	5.79e-05	0.000298	CcSEcCtD
Nicotine—Body temperature increased—Dexamethasone—psoriasis	5.79e-05	0.000298	CcSEcCtD
Nicotine—Abdominal pain—Dexamethasone—psoriasis	5.79e-05	0.000298	CcSEcCtD
Nicotine—Abdominal pain—Betamethasone—psoriasis	5.79e-05	0.000298	CcSEcCtD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.77e-05	0.000902	CbGpPWpGaD
Nicotine—Insomnia—Prednisone—psoriasis	5.77e-05	0.000297	CcSEcCtD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.75e-05	0.000899	CbGpPWpGaD
Nicotine—Nausea—Cyclosporine—psoriasis	5.73e-05	0.000295	CcSEcCtD
Nicotine—CYP2B6—skin of body—psoriasis	5.73e-05	0.021	CbGeAlD
Nicotine—Paraesthesia—Prednisone—psoriasis	5.73e-05	0.000295	CcSEcCtD
Nicotine—Pruritus—Triamcinolone—psoriasis	5.71e-05	0.000294	CcSEcCtD
Nicotine—Cough—Methotrexate—psoriasis	5.7e-05	0.000293	CcSEcCtD
Nicotine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.68e-05	0.000888	CbGpPWpGaD
Nicotine—CHRNB4—SIDS Susceptibility Pathways—TNF—psoriasis	5.68e-05	0.000887	CbGpPWpGaD
Nicotine—Dizziness—Hydrocortisone—psoriasis	5.67e-05	0.000292	CcSEcCtD
Nicotine—Convulsion—Methotrexate—psoriasis	5.66e-05	0.000291	CcSEcCtD
Nicotine—Dyspepsia—Prednisone—psoriasis	5.61e-05	0.000289	CcSEcCtD
Nicotine—CYP2A13—Metabolism—CARM1—psoriasis	5.59e-05	0.000874	CbGpPWpGaD
Nicotine—Nausea—Mycophenolate mofetil—psoriasis	5.59e-05	0.000288	CcSEcCtD
Nicotine—SLC22A3—Transmembrane transport of small molecules—CARM1—psoriasis	5.56e-05	0.000869	CbGpPWpGaD
Nicotine—Arthralgia—Methotrexate—psoriasis	5.56e-05	0.000286	CcSEcCtD
Nicotine—Chest pain—Methotrexate—psoriasis	5.56e-05	0.000286	CcSEcCtD
Nicotine—Myalgia—Methotrexate—psoriasis	5.56e-05	0.000286	CcSEcCtD
Nicotine—SLC22A5—Transmembrane transport of small molecules—CARM1—psoriasis	5.54e-05	0.000866	CbGpPWpGaD
Nicotine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	5.54e-05	0.000866	CbGpPWpGaD
Nicotine—Rash—Prednisolone—psoriasis	5.53e-05	0.000285	CcSEcCtD
Nicotine—Dermatitis—Prednisolone—psoriasis	5.53e-05	0.000284	CcSEcCtD
Nicotine—Fatigue—Prednisone—psoriasis	5.5e-05	0.000283	CcSEcCtD
Nicotine—Headache—Prednisolone—psoriasis	5.5e-05	0.000283	CcSEcCtD
Nicotine—Discomfort—Methotrexate—psoriasis	5.49e-05	0.000283	CcSEcCtD
Nicotine—Constipation—Prednisone—psoriasis	5.45e-05	0.000281	CcSEcCtD
Nicotine—MAOA—tendon—psoriasis	5.45e-05	0.02	CbGeAlD
Nicotine—Vomiting—Hydrocortisone—psoriasis	5.45e-05	0.00028	CcSEcCtD
Nicotine—Rash—Hydrocortisone—psoriasis	5.4e-05	0.000278	CcSEcCtD
Nicotine—Dermatitis—Hydrocortisone—psoriasis	5.4e-05	0.000278	CcSEcCtD
Nicotine—Confusional state—Methotrexate—psoriasis	5.37e-05	0.000277	CcSEcCtD
Nicotine—Headache—Hydrocortisone—psoriasis	5.37e-05	0.000276	CcSEcCtD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—JUN—psoriasis	5.36e-05	0.000839	CbGpPWpGaD
Nicotine—Dizziness—Triamcinolone—psoriasis	5.34e-05	0.000275	CcSEcCtD
Nicotine—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.33e-05	0.000834	CbGpPWpGaD
Nicotine—SLC22A3—Metabolism—CYP2S1—psoriasis	5.33e-05	0.000834	CbGpPWpGaD
Nicotine—Anaphylactic shock—Methotrexate—psoriasis	5.33e-05	0.000274	CcSEcCtD
Nicotine—Feeling abnormal—Prednisone—psoriasis	5.25e-05	0.00027	CcSEcCtD
Nicotine—Asthenia—Betamethasone—psoriasis	5.25e-05	0.00027	CcSEcCtD
Nicotine—Asthenia—Dexamethasone—psoriasis	5.25e-05	0.00027	CcSEcCtD
Nicotine—Nervous system disorder—Methotrexate—psoriasis	5.23e-05	0.000269	CcSEcCtD
Nicotine—Gastrointestinal pain—Prednisone—psoriasis	5.21e-05	0.000268	CcSEcCtD
Nicotine—Nausea—Prednisolone—psoriasis	5.21e-05	0.000268	CcSEcCtD
Nicotine—CHRNB2—Circadian rythm related genes—TP53—psoriasis	5.19e-05	0.000811	CbGpPWpGaD
Nicotine—Pruritus—Dexamethasone—psoriasis	5.18e-05	0.000267	CcSEcCtD
Nicotine—Pruritus—Betamethasone—psoriasis	5.18e-05	0.000267	CcSEcCtD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—NFKB1—psoriasis	5.16e-05	0.000807	CbGpPWpGaD
Nicotine—Hyperhidrosis—Methotrexate—psoriasis	5.15e-05	0.000265	CcSEcCtD
Nicotine—Vomiting—Triamcinolone—psoriasis	5.13e-05	0.000264	CcSEcCtD
Nicotine—Nausea—Hydrocortisone—psoriasis	5.09e-05	0.000262	CcSEcCtD
Nicotine—Rash—Triamcinolone—psoriasis	5.09e-05	0.000262	CcSEcCtD
Nicotine—Dermatitis—Triamcinolone—psoriasis	5.08e-05	0.000262	CcSEcCtD
Nicotine—Urticaria—Prednisone—psoriasis	5.07e-05	0.000261	CcSEcCtD
Nicotine—Headache—Triamcinolone—psoriasis	5.06e-05	0.00026	CcSEcCtD
Nicotine—Body temperature increased—Prednisone—psoriasis	5.04e-05	0.000259	CcSEcCtD
Nicotine—Abdominal pain—Prednisone—psoriasis	5.04e-05	0.000259	CcSEcCtD
Nicotine—SLC22A5—tendon—psoriasis	5.02e-05	0.0184	CbGeAlD
Nicotine—Diarrhoea—Betamethasone—psoriasis	5.01e-05	0.000258	CcSEcCtD
Nicotine—Diarrhoea—Dexamethasone—psoriasis	5.01e-05	0.000258	CcSEcCtD
Nicotine—Hypotension—Methotrexate—psoriasis	4.98e-05	0.000256	CcSEcCtD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—TNF—psoriasis	4.93e-05	0.00077	CbGpPWpGaD
Nicotine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	4.92e-05	0.000769	CbGpPWpGaD
Nicotine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.89e-05	0.000765	CbGpPWpGaD
Nicotine—Musculoskeletal discomfort—Methotrexate—psoriasis	4.86e-05	0.00025	CcSEcCtD
Nicotine—Dizziness—Dexamethasone—psoriasis	4.84e-05	0.000249	CcSEcCtD
Nicotine—Dizziness—Betamethasone—psoriasis	4.84e-05	0.000249	CcSEcCtD
Nicotine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.84e-05	0.000757	CbGpPWpGaD
Nicotine—Insomnia—Methotrexate—psoriasis	4.82e-05	0.000248	CcSEcCtD
Nicotine—Nausea—Triamcinolone—psoriasis	4.79e-05	0.000247	CcSEcCtD
Nicotine—Paraesthesia—Methotrexate—psoriasis	4.79e-05	0.000246	CcSEcCtD
Nicotine—Dyspnoea—Methotrexate—psoriasis	4.75e-05	0.000245	CcSEcCtD
Nicotine—CHRNB2—Circadian rythm related genes—IL6—psoriasis	4.75e-05	0.000743	CbGpPWpGaD
Nicotine—Somnolence—Methotrexate—psoriasis	4.74e-05	0.000244	CcSEcCtD
Nicotine—Hypersensitivity—Prednisone—psoriasis	4.7e-05	0.000242	CcSEcCtD
Nicotine—Dyspepsia—Methotrexate—psoriasis	4.69e-05	0.000241	CcSEcCtD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.69e-05	0.000733	CbGpPWpGaD
Nicotine—Vomiting—Dexamethasone—psoriasis	4.66e-05	0.00024	CcSEcCtD
Nicotine—Vomiting—Betamethasone—psoriasis	4.66e-05	0.00024	CcSEcCtD
Nicotine—MAOA—Metabolism—NDUFA5—psoriasis	4.65e-05	0.000727	CbGpPWpGaD
Nicotine—Rash—Betamethasone—psoriasis	4.62e-05	0.000238	CcSEcCtD
Nicotine—Rash—Dexamethasone—psoriasis	4.62e-05	0.000238	CcSEcCtD
Nicotine—Dermatitis—Dexamethasone—psoriasis	4.61e-05	0.000237	CcSEcCtD
Nicotine—Dermatitis—Betamethasone—psoriasis	4.61e-05	0.000237	CcSEcCtD
Nicotine—Gastrointestinal disorder—Methotrexate—psoriasis	4.6e-05	0.000237	CcSEcCtD
Nicotine—Fatigue—Methotrexate—psoriasis	4.59e-05	0.000236	CcSEcCtD
Nicotine—Headache—Betamethasone—psoriasis	4.59e-05	0.000236	CcSEcCtD
Nicotine—Headache—Dexamethasone—psoriasis	4.59e-05	0.000236	CcSEcCtD
Nicotine—CHRNB4—SIDS Susceptibility Pathways—IL6—psoriasis	4.58e-05	0.000716	CbGpPWpGaD
Nicotine—Asthenia—Prednisone—psoriasis	4.57e-05	0.000235	CcSEcCtD
Nicotine—Pain—Methotrexate—psoriasis	4.56e-05	0.000235	CcSEcCtD
Nicotine—CYP19A1—Metabolism—NDUFA5—psoriasis	4.54e-05	0.000709	CbGpPWpGaD
Nicotine—Pruritus—Prednisone—psoriasis	4.51e-05	0.000232	CcSEcCtD
Nicotine—Feeling abnormal—Methotrexate—psoriasis	4.39e-05	0.000226	CcSEcCtD
Nicotine—Diarrhoea—Prednisone—psoriasis	4.36e-05	0.000225	CcSEcCtD
Nicotine—Gastrointestinal pain—Methotrexate—psoriasis	4.36e-05	0.000224	CcSEcCtD
Nicotine—Nausea—Dexamethasone—psoriasis	4.35e-05	0.000224	CcSEcCtD
Nicotine—Nausea—Betamethasone—psoriasis	4.35e-05	0.000224	CcSEcCtD
Nicotine—Urticaria—Methotrexate—psoriasis	4.23e-05	0.000218	CcSEcCtD
Nicotine—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.23e-05	0.000661	CbGpPWpGaD
Nicotine—Dizziness—Prednisone—psoriasis	4.22e-05	0.000217	CcSEcCtD
Nicotine—Abdominal pain—Methotrexate—psoriasis	4.21e-05	0.000217	CcSEcCtD
Nicotine—Body temperature increased—Methotrexate—psoriasis	4.21e-05	0.000217	CcSEcCtD
Nicotine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	4.15e-05	0.000648	CbGpPWpGaD
Nicotine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.15e-05	0.000648	CbGpPWpGaD
Nicotine—CYP2E1—tendon—psoriasis	4.09e-05	0.015	CbGeAlD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.09e-05	0.000639	CbGpPWpGaD
Nicotine—Vomiting—Prednisone—psoriasis	4.05e-05	0.000209	CcSEcCtD
Nicotine—CHAT—Metabolism—CAT—psoriasis	4.04e-05	0.000632	CbGpPWpGaD
Nicotine—Rash—Prednisone—psoriasis	4.02e-05	0.000207	CcSEcCtD
Nicotine—Dermatitis—Prednisone—psoriasis	4.02e-05	0.000207	CcSEcCtD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—TNF—psoriasis	4.02e-05	0.000628	CbGpPWpGaD
Nicotine—Headache—Prednisone—psoriasis	3.99e-05	0.000206	CcSEcCtD
Nicotine—CHRNA7—SIDS Susceptibility Pathways—IL6—psoriasis	3.98e-05	0.000622	CbGpPWpGaD
Nicotine—MAOA—Metabolism—CYP2S1—psoriasis	3.95e-05	0.000618	CbGpPWpGaD
Nicotine—SLC22A2—Metabolism—NDUFA5—psoriasis	3.93e-05	0.000615	CbGpPWpGaD
Nicotine—Hypersensitivity—Methotrexate—psoriasis	3.93e-05	0.000202	CcSEcCtD
Nicotine—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	3.89e-05	0.000608	CbGpPWpGaD
Nicotine—MAOA—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.88e-05	0.000606	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism—CYP2S1—psoriasis	3.86e-05	0.000603	CbGpPWpGaD
Nicotine—Asthenia—Methotrexate—psoriasis	3.82e-05	0.000197	CcSEcCtD
Nicotine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	3.81e-05	0.000595	CbGpPWpGaD
Nicotine—Nausea—Prednisone—psoriasis	3.79e-05	0.000195	CcSEcCtD
Nicotine—Pruritus—Methotrexate—psoriasis	3.77e-05	0.000194	CcSEcCtD
Nicotine—SLC22A1—Metabolism—NDUFA5—psoriasis	3.67e-05	0.000573	CbGpPWpGaD
Nicotine—SLC22A2—Transmembrane transport of small molecules—CP—psoriasis	3.66e-05	0.000571	CbGpPWpGaD
Nicotine—Diarrhoea—Methotrexate—psoriasis	3.65e-05	0.000188	CcSEcCtD
Nicotine—CYP2A6—Metabolism—NDUFA5—psoriasis	3.61e-05	0.000565	CbGpPWpGaD
Nicotine—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	3.61e-05	0.000564	CbGpPWpGaD
Nicotine—MAOA—SIDS Susceptibility Pathways—JUN—psoriasis	3.61e-05	0.000564	CbGpPWpGaD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.53e-05	0.000552	CbGpPWpGaD
Nicotine—Dizziness—Methotrexate—psoriasis	3.52e-05	0.000181	CcSEcCtD
Nicotine—SLC22A2—Transmembrane transport of small molecules—CARM1—psoriasis	3.49e-05	0.000545	CbGpPWpGaD
Nicotine—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	3.47e-05	0.000543	CbGpPWpGaD
Nicotine—MAOA—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.47e-05	0.000543	CbGpPWpGaD
Nicotine—CYP2A13—Metabolism—CAT—psoriasis	3.44e-05	0.000538	CbGpPWpGaD
Nicotine—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	3.41e-05	0.000533	CbGpPWpGaD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.4e-05	0.000532	CbGpPWpGaD
Nicotine—Vomiting—Methotrexate—psoriasis	3.39e-05	0.000174	CcSEcCtD
Nicotine—Rash—Methotrexate—psoriasis	3.36e-05	0.000173	CcSEcCtD
Nicotine—Dermatitis—Methotrexate—psoriasis	3.36e-05	0.000173	CcSEcCtD
Nicotine—SLC22A2—Metabolism—CYP2S1—psoriasis	3.34e-05	0.000523	CbGpPWpGaD
Nicotine—Headache—Methotrexate—psoriasis	3.34e-05	0.000172	CcSEcCtD
Nicotine—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	3.25e-05	0.000508	CbGpPWpGaD
Nicotine—CHRNA4—SIDS Susceptibility Pathways—IL6—psoriasis	3.24e-05	0.000507	CbGpPWpGaD
Nicotine—Nausea—Methotrexate—psoriasis	3.17e-05	0.000163	CcSEcCtD
Nicotine—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	3.15e-05	0.000493	CbGpPWpGaD
Nicotine—MAOA—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.15e-05	0.000492	CbGpPWpGaD
Nicotine—CHAT—Metabolism—APOE—psoriasis	3.14e-05	0.000491	CbGpPWpGaD
Nicotine—SLC22A1—Metabolism—CYP2S1—psoriasis	3.12e-05	0.000487	CbGpPWpGaD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.09e-05	0.000482	CbGpPWpGaD
Nicotine—MAOB—Metabolism—CARM1—psoriasis	3.08e-05	0.000481	CbGpPWpGaD
Nicotine—CYP2A6—Metabolism—CYP2S1—psoriasis	3.07e-05	0.00048	CbGpPWpGaD
Nicotine—CYP2B6—Metabolism—NDUFA5—psoriasis	2.91e-05	0.000455	CbGpPWpGaD
Nicotine—CYP2E1—Metabolism—NDUFA5—psoriasis	2.85e-05	0.000446	CbGpPWpGaD
Nicotine—CHAT—Metabolism—PPARG—psoriasis	2.74e-05	0.000428	CbGpPWpGaD
Nicotine—MAOA—SIDS Susceptibility Pathways—TNF—psoriasis	2.7e-05	0.000422	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism—NDUFA5—psoriasis	2.69e-05	0.000421	CbGpPWpGaD
Nicotine—CYP2A13—Metabolism—APOE—psoriasis	2.67e-05	0.000418	CbGpPWpGaD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.64e-05	0.000413	CbGpPWpGaD
Nicotine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.64e-05	0.000413	CbGpPWpGaD
Nicotine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.62e-05	0.00041	CbGpPWpGaD
Nicotine—SLC22A3—Metabolism—CARM1—psoriasis	2.6e-05	0.000407	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.51e-05	0.000392	CbGpPWpGaD
Nicotine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.48e-05	0.000387	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism—NDUFA5—psoriasis	2.47e-05	0.000386	CbGpPWpGaD
Nicotine—CYP2E1—Metabolism—CYP2S1—psoriasis	2.43e-05	0.000379	CbGpPWpGaD
Nicotine—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	2.38e-05	0.000372	CbGpPWpGaD
Nicotine—CYP2A13—Metabolism—PPARG—psoriasis	2.33e-05	0.000364	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.3e-05	0.00036	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism—CYP2S1—psoriasis	2.29e-05	0.000358	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.2e-05	0.000344	CbGpPWpGaD
Nicotine—MAOA—SIDS Susceptibility Pathways—IL6—psoriasis	2.18e-05	0.000341	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism—CYP2S1—psoriasis	2.1e-05	0.000328	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.05e-05	0.000321	CbGpPWpGaD
Nicotine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.02e-05	0.000317	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.02e-05	0.000316	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.01e-05	0.000314	CbGpPWpGaD
Nicotine—MAOA—Metabolism—CARM1—psoriasis	1.93e-05	0.000302	CbGpPWpGaD
Nicotine—MAOB—Metabolism—CAT—psoriasis	1.89e-05	0.000296	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism—CARM1—psoriasis	1.88e-05	0.000295	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism—CYP2S1—psoriasis	1.87e-05	0.000293	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.87e-05	0.000293	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.76e-05	0.000275	CbGpPWpGaD
Nicotine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.72e-05	0.000269	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.72e-05	0.000268	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.71e-05	0.000267	CbGpPWpGaD
Nicotine—SLC22A2—Metabolism—CARM1—psoriasis	1.63e-05	0.000255	CbGpPWpGaD
Nicotine—SLC22A3—Metabolism—CAT—psoriasis	1.6e-05	0.00025	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.6e-05	0.00025	CbGpPWpGaD
Nicotine—SLC22A1—Metabolism—CARM1—psoriasis	1.52e-05	0.000238	CbGpPWpGaD
Nicotine—CYP2A6—Metabolism—CARM1—psoriasis	1.5e-05	0.000234	CbGpPWpGaD
Nicotine—MAOB—Metabolism—APOE—psoriasis	1.47e-05	0.00023	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.46e-05	0.000228	CbGpPWpGaD
Nicotine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.32e-05	0.000207	CbGpPWpGaD
Nicotine—MAOB—Metabolism—PPARG—psoriasis	1.28e-05	0.0002	CbGpPWpGaD
Nicotine—SLC22A3—Metabolism—APOE—psoriasis	1.24e-05	0.000195	CbGpPWpGaD
Nicotine—CYP2B6—Metabolism—CARM1—psoriasis	1.21e-05	0.000189	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.2e-05	0.000187	CbGpPWpGaD
Nicotine—MAOA—Metabolism—CAT—psoriasis	1.19e-05	0.000186	CbGpPWpGaD
Nicotine—CYP2E1—Metabolism—CARM1—psoriasis	1.18e-05	0.000185	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism—CAT—psoriasis	1.16e-05	0.000181	CbGpPWpGaD
Nicotine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.13e-05	0.000176	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism—CARM1—psoriasis	1.12e-05	0.000175	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.1e-05	0.000172	CbGpPWpGaD
Nicotine—SLC22A3—Metabolism—PPARG—psoriasis	1.08e-05	0.000169	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000163	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism—CARM1—psoriasis	1.02e-05	0.00016	CbGpPWpGaD
Nicotine—SLC22A2—Metabolism—CAT—psoriasis	1e-05	0.000157	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.81e-06	0.000153	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.57e-06	0.00015	CbGpPWpGaD
Nicotine—SLC22A1—Metabolism—CAT—psoriasis	9.36e-06	0.000146	CbGpPWpGaD
Nicotine—MAOA—Metabolism—APOE—psoriasis	9.23e-06	0.000144	CbGpPWpGaD
Nicotine—CYP2A6—Metabolism—CAT—psoriasis	9.22e-06	0.000144	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism—CARM1—psoriasis	9.14e-06	0.000143	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism—APOE—psoriasis	9e-06	0.000141	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.94e-06	0.00014	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.54e-06	0.000134	CbGpPWpGaD
Nicotine—CYP2D6—Metabolism—CARM1—psoriasis	8.41e-06	0.000131	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism—CARM1—psoriasis	8.34e-06	0.00013	CbGpPWpGaD
Nicotine—MAOA—Metabolism—PPARG—psoriasis	8.04e-06	0.000126	CbGpPWpGaD
Nicotine—CYP19A1—Metabolism—PPARG—psoriasis	7.84e-06	0.000123	CbGpPWpGaD
Nicotine—SLC22A2—Metabolism—APOE—psoriasis	7.81e-06	0.000122	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.79e-06	0.000122	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.64e-06	0.00012	CbGpPWpGaD
Nicotine—CYP2B6—Metabolism—CAT—psoriasis	7.44e-06	0.000116	CbGpPWpGaD
Nicotine—CYP2E1—Metabolism—CAT—psoriasis	7.29e-06	0.000114	CbGpPWpGaD
Nicotine—SLC22A1—Metabolism—APOE—psoriasis	7.28e-06	0.000114	CbGpPWpGaD
Nicotine—CYP2A6—Metabolism—APOE—psoriasis	7.17e-06	0.000112	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism—CARM1—psoriasis	7.12e-06	0.000111	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism—CAT—psoriasis	6.87e-06	0.000107	CbGpPWpGaD
Nicotine—SLC22A2—Metabolism—PPARG—psoriasis	6.8e-06	0.000106	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.66e-06	0.000104	CbGpPWpGaD
Nicotine—SLC22A1—Metabolism—PPARG—psoriasis	6.34e-06	9.91e-05	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism—CAT—psoriasis	6.3e-06	9.85e-05	CbGpPWpGaD
Nicotine—CYP2A6—Metabolism—PPARG—psoriasis	6.24e-06	9.76e-05	CbGpPWpGaD
Nicotine—CYP2B6—Metabolism—APOE—psoriasis	5.78e-06	9.04e-05	CbGpPWpGaD
Nicotine—CYP2E1—Metabolism—APOE—psoriasis	5.66e-06	8.85e-05	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism—CAT—psoriasis	5.62e-06	8.79e-05	CbGpPWpGaD
Nicotine—CYP3A4—Metabolism—CARM1—psoriasis	5.5e-06	8.59e-05	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism—APOE—psoriasis	5.34e-06	8.35e-05	CbGpPWpGaD
Nicotine—CYP2D6—Metabolism—CAT—psoriasis	5.17e-06	8.09e-05	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism—CAT—psoriasis	5.13e-06	8.02e-05	CbGpPWpGaD
Nicotine—CYP2B6—Metabolism—PPARG—psoriasis	5.04e-06	7.87e-05	CbGpPWpGaD
Nicotine—CYP2E1—Metabolism—PPARG—psoriasis	4.93e-06	7.71e-05	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism—APOE—psoriasis	4.89e-06	7.65e-05	CbGpPWpGaD
Nicotine—CYP1A1—Metabolism—PPARG—psoriasis	4.65e-06	7.27e-05	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism—CAT—psoriasis	4.38e-06	6.85e-05	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism—APOE—psoriasis	4.37e-06	6.83e-05	CbGpPWpGaD
Nicotine—CYP2C8—Metabolism—PPARG—psoriasis	4.26e-06	6.67e-05	CbGpPWpGaD
Nicotine—CYP2D6—Metabolism—APOE—psoriasis	4.02e-06	6.28e-05	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism—APOE—psoriasis	3.98e-06	6.23e-05	CbGpPWpGaD
Nicotine—CYP2C19—Metabolism—PPARG—psoriasis	3.81e-06	5.95e-05	CbGpPWpGaD
Nicotine—CYP2D6—Metabolism—PPARG—psoriasis	3.5e-06	5.47e-05	CbGpPWpGaD
Nicotine—CYP2C9—Metabolism—PPARG—psoriasis	3.47e-06	5.42e-05	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism—APOE—psoriasis	3.4e-06	5.32e-05	CbGpPWpGaD
Nicotine—CYP3A4—Metabolism—CAT—psoriasis	3.38e-06	5.29e-05	CbGpPWpGaD
Nicotine—CYP1A2—Metabolism—PPARG—psoriasis	2.97e-06	4.64e-05	CbGpPWpGaD
Nicotine—CYP3A4—Metabolism—APOE—psoriasis	2.63e-06	4.11e-05	CbGpPWpGaD
Nicotine—CYP3A4—Metabolism—PPARG—psoriasis	2.29e-06	3.58e-05	CbGpPWpGaD
